Definium Therapeutics (NASDAQ:DFTX) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Definium Therapeutics (NASDAQ:DFTX) from a hold rating to a sell rating in a research note released on Saturday morning.

Several other research firms have also commented on DFTX. JonesTrading lifted their price target on shares of Definium Therapeutics from $61.00 to $74.00 and gave the company a “buy” rating in a report on Wednesday, June 24th. Canaccord Genuity Group set a $58.00 price objective on shares of Definium Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, June 30th. Robert W. Baird increased their price objective on shares of Definium Therapeutics from $37.00 to $57.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 23rd. Oppenheimer set a $60.00 target price on shares of Definium Therapeutics and gave the stock an “outperform” rating in a report on Monday, June 22nd. Finally, Royal Bank Of Canada restated an “outperform” rating on shares of Definium Therapeutics in a research note on Monday, June 22nd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Definium Therapeutics presently has an average rating of “Buy” and an average target price of $55.00.

Definium Therapeutics Stock Performance

Shares of DFTX opened at $45.15 on Friday. The business’s fifty day moving average price is $38.32 and its 200 day moving average price is $26.16. Definium Therapeutics has a 12-month low of $8.70 and a 12-month high of $49.70. The stock has a market capitalization of $4.50 billion, a PE ratio of -13.16 and a beta of 2.23. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.95 and a quick ratio of 6.95.

Definium Therapeutics (NASDAQ:DFTX) last released its earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.89). Equities research analysts forecast that Definium Therapeutics will post -2.27 EPS for the current year.

Insider Activity

In other news, insider Matthew T. Wiley sold 2,867 shares of the business’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $129,101.01. Following the completion of the transaction, the insider owned 174,633 shares of the company’s stock, valued at approximately $7,863,723.99. The trade was a 1.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Robert Barrow sold 29,208 shares of the stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $1,315,236.24. Following the completion of the sale, the chief executive officer directly owned 1,098,246 shares in the company, valued at approximately $49,454,017.38. This trade represents a 2.59% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 48,096 shares of company stock worth $2,165,763. 2.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Definium Therapeutics

Large investors have recently made changes to their positions in the company. Russell Investments Group Ltd. raised its holdings in shares of Definium Therapeutics by 110.4% during the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after buying an additional 2,003 shares during the last quarter. BNP Paribas Financial Markets increased its position in Definium Therapeutics by 56.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock valued at $55,000 after acquiring an additional 3,020 shares during the period. Flagship Harbor Advisors LLC acquired a new stake in Definium Therapeutics in the 4th quarter valued at approximately $117,000. Caxton Associates LLP bought a new stake in Definium Therapeutics during the 3rd quarter valued at $126,000. Finally, Mercer Global Advisors Inc. ADV raised its stake in Definium Therapeutics by 10.5% during the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company’s stock valued at $259,000 after acquiring an additional 2,079 shares in the last quarter. Institutional investors and hedge funds own 27.91% of the company’s stock.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.